DionyMed Holdings Inc. Announces the Closing of Approximately C$35 Million of Private Placement Subscription Receipts and Conditional Listing Approval by the CSE

Saturday, November 24, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

TORONTO, Nov. 23, 2018 /CNW/ -áDionyMed Holdings Inc. ("DionyMed"), a multi-state cannabis brand and distribution platform,

is pleased to announce that it has completed the previously announced private placement of subscription receipts (each, a "Subscription Receipt") at a price of C$4.25 (the "Issue Price") per Subscription Receipt for aggregate
gross proceeds of approximatelyáC$35,000,000 (the "Offering").

Additionally, DionyMed Holdings Inc. and Sixonine Ventures Corp. ("Sixonine") are pleased to announce that the Canadian Securities Exchange (the "CSE") has provided conditional approval of the listing of the subordinate voting shares of Sixonine (the "Subordinate Voting Shares") under the trading symbol "DYME", which listing is anticipated to occur shortly following the completion of the previously announced business combination of Sixonine and DionyMed Holdings Inc. (the "RTO"). Upon completion of the RTO, Sixonine is to be renamed "DionyMed Brands Inc." Sixonine following the RTO and name change is referred to as the "Company" or "DYME".

"Our recent successful capital raise of approximatelyáC$35 million and anticipated listing on the CSE are significant milestones in our company's exciting narrative.áWe have grown from inception in 2017, to become one of the leading providers of branded products, distribution and direct to consumer services in the U.S. legal cannabis market," commented Edward Fields, CEO of DionyMed. "Our anticipated listing on the CSE provides direct access for investors to participate in our rapidly growing legal cannabis story as we outpace our peers and expand across the United States."á

The listing of the Subordinate Voting Shares is subject to, among other things, satisfaction of the customary listing conditions of the CSE and the completion of the RTO as contemplated in the agreement dated October 2, 2018 between DionyMed and Sixonine. Subject to satisfaction of these and other conditions, a subsequent announcement will be made regarding the expected date for the commencement of trading.

A listing statement describing the Company, prepared in accordance with the policies of the CSE, will be made available on SEDAR at www.sedar.com. The information regarding the Company and the RTO in this press release is qualified in its entirety by reference to the more detailed disclosure included in the listing statement.

About DionyMed

Founded in 2017, DionyMed is a rapidly-growing, multi-state cannabis brands and distribution platform, supporting cultivators, manufacturers and award-winning brands in the medical and adult-use cannabis markets. DionyMed entered the cannabis industry in the vape cartridge manufacturing category and following California's adult-use legalization in January 2018, expanded from manufacturing into distribution. DionyMed sells branded products in every category from flower to vape cartridges, concentrates and edibles. DionyMed serves more than 700 dispensaries and completes over 40,000 Direct-To-Consumer deliveries each month with its growing portfolio of products and brands.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities of DionyMed in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information and Statements

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but are not limited to, expectations regarding whether the RTO will be consummated, including whether conditions to the consummation of the RTO will be satisfied and the timing for completing the RTO, expectations for the effects of the RTO or the ability of the combined company to successfully achieve business objectives, expectations regarding satisfaction of the listing conditions of the CSE, timing of the listing of the Subordinate Voting Shares on the CSE, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: the ability to consummate the RTO and the listing conditions of the CSE; the satisfaction of other conditions to the consummation of the RTO or the listing of the Subordinate Voting Shares on the CSE on the proposed terms and schedule; the potential impact of the announcement or consummation of the RTO on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the RTO. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE DionyMed Holdings Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store